ATRA — Atara Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $94.70m
- $127.81m
- $120.77m
Atara Biotherapeutics Q1 revenue drops after prior-year one-time gain
Brief: Atara Biotherapeutics Q1 EPS USD -0.29
NASDAQ RESUMED AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:30 PM
Atara more than doubles after FDA backs re-submission of cancer drug application
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
NASDAQ RESUMED AT 12:19 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:14 PM
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
NASDAQ RESUMED AT 10:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:50 AM
Atara jumps after US FDA backs re-submission of cancer drug application
Brief: Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
Brief: Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
US FDA declines to approve Atara's therapy for rare blood cancer (updated)
Atara Biotherapeutics sinks as FDA rejects cancer drug application
Brief: Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA
US FDA declines to approve Atara's therapy for rare blood cancer